| Bioactivity | STX140 is an orally active microtubule disruptor. STX140 induces apoptosis in the hormone-independent PC-3 prostate cell lines. STX140 has anti-angiogenic and anti-tumour activities[1]. |
| Invitro | STX140 是前列腺和乳腺癌细胞系中细胞增殖的强效抑制剂，对 PC-3、MDA-MB-231、LNCaP、MCF-7、A2780 和 HUVEC 的 IC50 值分别为 270 nM、290 nM、260 nM、250 nM、280 nM 和 44 nM[1]。STX140 (0.5 μM; 24 h) 可强效诱导细胞周期停滞。 STX140 诱导激素非依赖性 PC-3 前列腺细胞系凋亡[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> STX140 相关抗体: Cell Cycle Analysis[1] Cell Line: |
| In Vivo | STX140（20 mg/kg；口服；每日一次；60 天）可导致肿瘤消退和完全缓解，在停止给药后仍可维持[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 401600-86-0 |
| Formula | C19H28N2O7S2 |
| Molar Mass | 460.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. S P Newman, et al. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Br J Cancer. 2007 Dec 17;97(12):1673-82. |